TY - JOUR
T1 - Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma
AU - Chang, Hong
AU - Stewart, A. Keith
AU - Qi, Xiao Ying
AU - Li, Zhi Hua
AU - Yi, Qi Long
AU - Trudel, Suzanne
PY - 2005/7/1
Y1 - 2005/7/1
N2 - The t(4;14) translocation detected by fluorescence in situ hybridization (FISH) is an independent prognostic factor for an adverse outcome of multiple myeloma (MM). Because t(4;14) uniquely results in fibroblast growth factor receptor 3 (FGFR3) expression, decalcified, paraffin-embedded bone marrow biopsies were immunostained for FGFR3, and its expression was correlated with the t(4;14) status, FISH detected t(4;14) in 16 (19%) of 85 MM patient specimens, and immunocytochemistry detected aberrant FGFR3 expression in 13 (15%). Twelve (75%) t(4;14)-positive cases expressed FGFR3, and 12 (92%) FGFR3-positive cases harbored a t(4;14). FGFR3 expression and t(4;14) were strongly correlated (P < .001). FGFR3 expression by immunohistochemistry was associated with the immunoglobulin A (IgA) isotype (P < .001), a shorter progression-free survival (median, 11.5 versus 25.8 months; P < .001), and a shorter overall survival (median, 19.2 versus 46.3 months; P < .001).
AB - The t(4;14) translocation detected by fluorescence in situ hybridization (FISH) is an independent prognostic factor for an adverse outcome of multiple myeloma (MM). Because t(4;14) uniquely results in fibroblast growth factor receptor 3 (FGFR3) expression, decalcified, paraffin-embedded bone marrow biopsies were immunostained for FGFR3, and its expression was correlated with the t(4;14) status, FISH detected t(4;14) in 16 (19%) of 85 MM patient specimens, and immunocytochemistry detected aberrant FGFR3 expression in 13 (15%). Twelve (75%) t(4;14)-positive cases expressed FGFR3, and 12 (92%) FGFR3-positive cases harbored a t(4;14). FGFR3 expression and t(4;14) were strongly correlated (P < .001). FGFR3 expression by immunohistochemistry was associated with the immunoglobulin A (IgA) isotype (P < .001), a shorter progression-free survival (median, 11.5 versus 25.8 months; P < .001), and a shorter overall survival (median, 19.2 versus 46.3 months; P < .001).
UR - http://www.scopus.com/inward/record.url?scp=22044440001&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22044440001&partnerID=8YFLogxK
U2 - 10.1182/blood-2005-01-0033
DO - 10.1182/blood-2005-01-0033
M3 - Article
C2 - 15761022
AN - SCOPUS:22044440001
SN - 0006-4971
VL - 106
SP - 353
EP - 355
JO - Blood
JF - Blood
IS - 1
ER -